Artificial intelligence‐quantified schisis volume as a structural endpoint for gene therapy clinical trials in X‐linked retinoschisis
ASV measurements can track changes in schisis volume in response to treatment. As an endpoint, ASV has a greater statistical effect size than CST/CFT, which reduces sample size requirements for future XLRS gene therapy clinical trials.
Authors
- Rick Siow Mong Goh (ORCID: https://orcid.org/0000-0001-9116-1595)
- Petèr Király (ORCID: https://orcid.org/0000-0002-7980-4401)
- Beau J. Fenner (ORCID: https://orcid.org/0000-0002-5356-7604)
- Tien‐En Tan (ORCID: https://orcid.org/0000-0002-9869-5159)
- Peilun Dai (ORCID: https://orcid.org/0000-0002-1680-0526)
- Daniel Shu Wei Ting (ORCID: https://orcid.org/0000-0003-2264-7174)
- Jonathan Hensman (ORCID: https://orcid.org/0000-0002-2925-8940)
- Camiel J.F. Boon (ORCID: https://orcid.org/0000-0002-6737-7932)
- Ian C. Han (ORCID: https://orcid.org/0000-0002-2371-727X)
- Yong Liu (ORCID: https://orcid.org/0000-0002-2966-7867)
- M. Dominik Fischer (ORCID: https://orcid.org/0000-0002-0690-6538)
Institutions
- Agency for Science, Technology and Research (SG)
- University of Iowa (US)
- Singapore National Eye Center (SG)
- Leiden University Medical Center (NL)
- Nuffield Orthopaedic Centre (GB)
- Institute of High Performance Computing (SG)
- University of Oxford (GB)
- Singapore Eye Research Institute (SG)
- Duke-NUS Medical School (SG)
- STZ eyetrial (DE)
- Oxford University Hospitals NHS Trust (GB)
- Amsterdam University Medical Centers (NL)
Publication Details
- Journal
- Acta Ophthalmologica
- Published
- 2025-03-29
- DOI
- https://doi.org/10.1111/aos.17485
- Citations
- 3
- Primary Topic
- Retinal Development and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- Duke-NUS Medical School
- Agency for Science, Technology and Research
- Astellas Pharma
- Russian Science Foundation
- Medical Research Council
- National Medical Research Council